

# Long Call

A service of the [U.S. National Library of Medicine](#) and the [National Institutes of Health](#) My NCBI [?](#)  
Welcome maylward. [Sign Out](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for    [Advanced Search](#)

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy 

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Limits Preview/Index History Clipboard Details

Display Abstract Show 20 Sort By Send to

All: 1 Clinical Trial: 0 Items with Abstracts: 1 Published in the last 5 years: 1 Review: 0

1: [Curr Treat Options Gastroenterol.](#) 2006 Jun;9(3):265-71.

[Related Articles,](#)  
[Links](#)

Current  
Treatment Options

CLICK  
HERE TO  
READ



## Update on Clostridium difficile.

[Thorpe CM](#), [Gorbach SL](#).

Department of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, 750 Washington Street, Box 041, Boston, MA 02111, USA. [cthorge@tufts-nemc.org](mailto:cthorge@tufts-nemc.org).

The most dramatic change in the past several years has been the increased incidence and severity of Clostridium difficile colitis reported from multiple countries. A number of factors have likely contributed to this. One major event has been the emergence of a fluoroquinolone-resistant clone of C. difficile with enhanced virulence properties that is associated with epidemic disease. Also noteworthy is the apparently decreasing effectiveness of the first-line agent metronidazole in treating this disease. Aggressive treatment of severe C. difficile colitis requires a multifaceted approach, including: 1) cessation of antibiotics where possible; 2) oral vancomycin; 3) if an ileus exists, intravenous administration of metronidazole and possibly intracolonic administration of vancomycin; 4) intravenous immunoglobulin if response to therapy is not rapid, or if there are signs of sepsis; and 5) early surgical consultation. Although it is likely that intravenous immunoglobulin contains antibodies against C. difficile toxins, its benefit remains unproven in rigorous clinical trials. Efforts to actively or passively immunize patients at risk are being explored to prevent the increasing morbidity and mortality associated with this disease. However, defining exactly who is at risk for severe C. difficile-associated disease is complex, as cases are being reported in populations not previously believed to be vulnerable.

PMID: 16901390 [PubMed - in process]

Display Abstract Show 20 Sort By Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)


[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

A service of the U.S. National Library of Medicine  
and the National Institutes of Health

My NCBI

Welcome maylward. [\[Sign Out\]](#)All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search PubMed for    [Advanced Search](#)[About Entrez](#)  
[Text Version](#)[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)Display  Show  Sort By  Send to  All: 1  Clinical Trial: 0  Items with Abstracts: 1  Published in the last 5 years: 0  Review: 1

## Entrez PubMed

[Overview](#)  
[Help | FAQ](#)  
[Tutorials](#)  
[New/Noteworthy](#)   
[E-Utilities](#)

## PubMed Services

[Journals Database](#)  
[MeSH Database](#)  
[Single Citation](#)  
[Matcher](#)  
[Batch Citation Matcher](#)  
[Clinical Queries](#)  
[Special Queries](#)  
[LinkOut](#)  
[My NCBI](#)

## Related Resources

[Order Documents](#)  
[NLM Mobile](#)  
[NLM Catalog](#)  
[NLM Gateway](#)  
[TOXNET](#)  
[Consumer Health](#)  
[Clinical Alerts](#)  
[ClinicalTrials.gov](#)  
[PubMed Central](#) 1: [Clin Infect Dis.](#) 2002 Sep 15;35(6):690-6. Epub 2002 Aug 26.[Related Articles,](#)  
[Links](#)

Comment in:

- [Curr Surg. 2003 May-Jun;60\(3\):227-30.](#)
- [Rev Gastroenterol Disord. 2003 Fall;3\(4\):228-9.](#)

**Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature.**[Apisarnthanarak A](#), [Razavi B](#), [Mundy LM](#).

Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Successful treatment of severe Clostridium difficile colitis has been reported with the use of adjunctive intracolonic vancomycin (ICV) therapy. We report a descriptive case series and review the literature on patients with C. difficile colitis who received adjunctive ICV therapy. Nine patients received antibiotics within 6 weeks prior to presentation. Complete resolution of the clinical presentation occurred in 8 patients (88.9%), and eradication of C. difficile cytotoxin production was documented in 3 (75%) of 4 patients who were tested after the completion of adjunctive ICV therapy. One patient (11.1%) died as a result of progressive multisystem organ failure. In the 6 weeks after the completion of treatment for C. difficile colitis, no patient had recurrent disease, required surgical intervention, or experienced complications from adjunctive ICV therapy. In this case series, administration of adjunctive ICV therapy appeared to be a safe, practical, and effective adjunctive therapy for severe C. difficile colitis.

Publication Types:

- [Case Reports](#)
- [Review](#)

PMID: 12203166 [PubMed - indexed for MEDLINE]

Display  Show  Sort By  Send to [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

# Second Reading

## Long Call Events

Dr. R Heya -- Ct scan shows diffusely edematous colon, no free air, consistent with toxic megacolon.

Mr. Fused -- Follow-up potassium was 4.5, nothing done.

Mrs. D. Monas -- Fever, cultured, repeat CXR unchanged.

Ms. Payne -- Nothing.

# Third Reading

Read the **Checklist** on the following  
page in your packet and be prepared to observe  
and provide feedback on a hand-off.

## Hand-Off Observation Checklist

During the Hand-Off, did you observe the participants perform the following skills:

Yes

No

Triage & Prioritize -- Detail and history given more on complex patients, less on simple ones

“Tell the Story” -- gives a succinct, relevant presentation

“Details on Demand” -- interactive questioning of status/assumptions

Contingency Plans -- For every follow-up item, there is an If...then type statement